CGON - CG Oncology, Inc. Common stock

CGON - CG Oncology, Inc. Common stock

https://cgoncology.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

CG Oncology Stock Signals Bullish Momentum Ahead - CG Oncology ( NASDAQ:CGON )

Benzinga • 1 week ago • score: 0.12

CG Oncology CGON has moved into Phase 2 of its 18-phase Adhishthana cycle, a critical stage that often sets the tone for early bullish momentum. Within this phase, the stock transitions into what's called the Buddhi move period, where breakouts are more likely to unfold.

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months - CG Oncology ( NASDAQ:CGON )

Benzinga • 1 week, 3 days ago

- Robust 24-month complete response ( CR ) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer ( NMIBC ) who are unresponsive to Bacillus Calmette Guerin ( BCG ) treatment - - 90% of 12-month responders remained disease free at 24 ...

CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences - CG Oncology ( NASDAQ:CGON )

Benzinga • 2 weeks, 3 days ago • score: 0.11

IRVINE, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc.

CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences

GlobeNewswire • 2 weeks, 3 days ago • score: 0.16

IRVINE, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc. ( NASDAQ: CGON ) , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, ...

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire • 1 month, 1 week ago • score: 0.10

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting -

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$40.47

52W Low

$14.80

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

3378.31

P/S (TTM) (<3 favorable)

4576.24

P/B (<3 favorable)

3.76

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.17%

Institutions (25–75% balanced)

112.63%

Shares Outstanding

76,248,000

Float

61,280,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

551,000

Gross Profit (TTM)

-84,184,000

EPS (TTM)

-1.78

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-285.46%

ROE (TTM) (>15% strong)

-0.17%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.90

Momentum

Bearish momentum

Value

1.4413

Previous

0.9273

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025